Technical Analysis for RPHM - Reneo Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.64 | -1.20% | -0.02 |
RPHM closed down 1.2 percent on Monday, March 18, 2024, on 52 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Mar 25
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
20 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Crossed Above 20 DMA | Bullish | -1.20% | |
Crossed Above 50 DMA | Bullish | -1.20% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | -1.20% | |
Bollinger Band Squeeze | Range Contraction | -1.20% | |
BB Squeeze + Lower Band Touch | Range Contraction | -1.20% | |
BB Squeeze + Upper Band Touch | Range Contraction | -1.20% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 11 hours ago |
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
50 DMA Support | about 14 hours ago |
Fell Below 20 DMA | about 14 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/25/2024
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.295 |
52 Week Low | 0.9801 |
Average Volume | 330,524 |
200-Day Moving Average | 5.35 |
50-Day Moving Average | 1.65 |
20-Day Moving Average | 1.63 |
10-Day Moving Average | 1.63 |
Average True Range | 0.07 |
RSI (14) | 44.75 |
ADX | 15.63 |
+DI | 17.10 |
-DI | 15.78 |
Chandelier Exit (Long, 3 ATRs) | 1.51 |
Chandelier Exit (Short, 3 ATRs) | 1.76 |
Upper Bollinger Bands | 1.67 |
Lower Bollinger Band | 1.59 |
Percent B (%b) | 0.62 |
BandWidth | 4.59 |
MACD Line | -0.04 |
MACD Signal Line | -0.06 |
MACD Histogram | 0.0181 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.70 | ||||
Resistance 3 (R3) | 1.70 | 1.68 | 1.69 | ||
Resistance 2 (R2) | 1.68 | 1.66 | 1.68 | 1.69 | |
Resistance 1 (R1) | 1.66 | 1.66 | 1.65 | 1.66 | 1.68 |
Pivot Point | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 |
Support 1 (S1) | 1.62 | 1.62 | 1.61 | 1.62 | 1.60 |
Support 2 (S2) | 1.60 | 1.62 | 1.60 | 1.59 | |
Support 3 (S3) | 1.58 | 1.60 | 1.59 | ||
Support 4 (S4) | 1.58 |